Leukemia
Researchers uncover new subtype of pediatric AML defined by UBTF tandem duplications
Upstream binding transcription factor tandem duplications, or UBTF-TDs, identified through integrated genomic analysis represent a new subtype of acute myeloid leukemia that previously had no known oncogenic driver, study results showed.
Umbralisib plus ublituximab benefits patients with CLL and Bruton TKI risk factors
The combination of umbralisib and ublituximab demonstrated superior PFS and overall response rates compared with chemoimmunotherapy among patients with chronic lymphocytic leukemia and Bruton tyrosine kinase inhibitor risk factors.
Minimal residual disease negativity key to durable remissions after CAR-T for CLL
Minimal residual disease status appeared to influence outcomes after chimeric antigen receptor T-cell therapy for high-risk chronic lymphocytic leukemia, according to study results.
CAR-T provides value despite high price tag, oncologists say
Sixty percent of hematologist-oncologists believe chimeric antigen receptor T-cell therapies provide clinical value at their current price, according to survey results presented at ASH Annual Meeting and Exposition.
COVID-19 more severe in patients with active acute leukemia, myelodysplastic syndrome
Patients with acute leukemia or myelodysplastic syndrome in an active state experienced significantly greater COVID-19 severity but not higher mortality due to the virus, according to research presented at ASH Annual Meeting and Exposition.
Addition of gilteritinib to azacitidine may benefit certain patients with FLT-mutated AML
Gilteritinib plus azacitidine conferred significantly higher complete remission rates, but similar OS, vs. azacitidine among patients with newly diagnosed, FLT3-mutated acute myeloid leukemia ineligible for intensive induction chemotherapy.
Venetoclax-based time-limited combination therapies show efficacy in CLL
Time-limited venetoclax-based combination therapies conferred superior rates of undetectable minimal residual disease compared with chemoimmunotherapy among fit patients with chronic lymphocytic leukemia, study results showed.
Ibrutinib plus chemoimmunotherapy confers durable responses in younger patients with CLL
Most patients with chronic lymphocytic leukemia who received ibrutinib plus fludarabine, cyclophosphamide and rituximab continued to maintain deep responses after longer-term follow-up, results of a single arm, phase 2 trial showed.
AML in younger Black AYAs molecularly distinct, associated with shorter survival
Younger Black patients with acute myeloid leukemia had worse outcomes than their white counterparts, including a higher early death rate, numerically lower complete remission rate and shorter OS, according to study results.
Addition of venetoclax to azacitidine improves outcomes for subset of patients with AML
Treatment with venetoclax plus azacitidine conferred better outcomes than azacitidine alone among select patients with acute myeloid leukemia, according to study results presented at ASH Annual Meeting and Exposition.